Literature DB >> 28127890

MicroRNA profile analysis in the liver fibrotic tissues of chronic hepatitis B patients.

Rong Chen1, Jun Cheng Wu1, Ting Liu1, Ying Qu1, Lun Gen Lu1, Ming Yi Xu1.   

Abstract

OBJECTIVE: We aimed to identify the features of microRNA (miRNA) at different fibrotic stages in patients with hepatitis B virus (HBV)-related liver fibrosis.
METHODS: Liver tissues were collected from 40 chronic hepatitis B (CHB) patients at fibrotic stages S0-4. Microarrays of miRNAs and genomic informatics analysis were performed.
RESULTS: In total, 105 miRNAs were differentially expressed in fibrotic tissues (S1-4 groups) compared with no fibrotic tissues (S0 group; P < 0.05). Combined with three classifications, 17 differential miRNAs were found to be closely related to fibrotic stages (over twofold change and P < 0.05). Five miRNAs had a signature that correlated with serum biochemical parameters and liver inflammatory grades. The receiver operating characteristic (ROC) curve showed that six miRNAs performed excellently in the diagnosis of liver fibrosis, with the area under the ROC curve (AUROC) over 0.8; among them hsa-miR-214-3p had the highest AUROC (0.867). Gene ontology functions of differential miRNAs mainly involved in the cellular and developmental processes, localization, biological regulation, binding, transcriptional regulator and organelle. We also found that 23 novel signaling pathways were dysregulated in the liver fibrosis.
CONCLUSIONS: MiRNA profile signature, including 17 differential miRNAs and 23 dysregulated signaling pathways, was associated with liver fibrosis. Hepatic inflammatory grades were correlated with the differential miRNA. Some miRNAs can be used for the diagnosis of liver fibrosis.
© 2017 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  chronic hepatitis Bzzm321990; fibrosis; liver cirrhosis; microRNAs; microarray analysis

Mesh:

Substances:

Year:  2017        PMID: 28127890     DOI: 10.1111/1751-2980.12452

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  7 in total

1.  Exploring the underlying molecular mechanism of liver cancer cells under hypoxia based on RNA sequencing.

Authors:  Xin Zhao; Wenpeng Liu; Baowang Liu; Qiang Zeng; Ziqiang Cui; Yang Wang; Jinglin Cao; Qingjun Gao; Caiyan Zhao; Jian Dou
Journal:  BMC Genom Data       Date:  2022-05-19

Review 2.  Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA.

Authors:  Kazuma Sekiba; Motoyuki Otsuka; Motoko Ohno; Mari Yamagami; Takahiro Kishikawa; Tatsunori Suzuki; Rei Ishibashi; Takahiro Seimiya; Eri Tanaka; Kazuhiko Koike
Journal:  World J Gastroenterol       Date:  2018-06-07       Impact factor: 5.742

Review 3.  The Regulatory Role of MicroRNA in Hepatitis-B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) Pathogenesis.

Authors:  Kurt Sartorius; Julia Makarova; Benn Sartorius; Ping An; Cheryl Winkler; Anil Chuturgoon; Anna Kramvis
Journal:  Cells       Date:  2019-11-24       Impact factor: 6.600

4.  The Diagnosis Value of a Novel Model with 5 Circulating miRNAs for Liver Fibrosis in Patients with Chronic Hepatitis B.

Authors:  Qingqing Zhang; Qidi Zhang; Binghang Li; Ying Qu; Zhenghong Li; Lungen Lu; Rongzhou Li; Xiaobo Cai
Journal:  Mediators Inflamm       Date:  2021-03-01       Impact factor: 4.711

5.  Safety and long-term outcomes of early gastric cardiac cancer treated with endoscopic submucosal dissection in 499 Chinese patients.

Authors:  Shouli Cao; Tianhui Zou; Qi Sun; Tianyun Liu; Ting Fan; Qin Yin; Xiangshan Fan; Jingwei Jiang; Dekusaah Raymond; Yi Wang; Bin Zhang; Ying Lv; Xiaoqi Zhang; Tingsheng Ling; Yuzheng Zhuge; Lei Wang; Xiaoping Zou; Guifang Xu; Qin Huang
Journal:  Therap Adv Gastroenterol       Date:  2020-10-20       Impact factor: 4.409

6.  Human hepatocyte-enriched miRNA-192-3p promotes HBV replication through inhibiting Akt/mTOR signalling by targeting ZNF143 in hepatic cell lines.

Authors:  Fahong Li; Yingying Deng; Shenyan Zhang; Beidi Zhu; Jun Wang; Jinyu Wang; Xueyu Wang; Zhenyu Zhao; Wanyu Deng; Richeng Mao; Zhongliang Shen; Jieliang Chen; Ruth Broering; Yong Lin; Mengji Lu; Jiming Zhang
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 7.163

7.  MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis.

Authors:  Yue Li; You Li; Yao Chen; Qian Xie; Ningning Dong; Yanjun Gao; Huan Deng; Chunhua Lu; Suihai Wang
Journal:  Cancer Cell Int       Date:  2017-11-07       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.